Uncategorized

Clinics, Dispensing and Northwind Pharmaceuticals

Welcome to the first blog devoted to clinic dispensing and practice development. My name is Phil Berry and I’m the owner of Northwind Pharmaceuticals in Indianapolis, Indiana.  Since 1981, NWP has worked with clinics across the country to help them serve their patients with prepackaged pharmaceuticals and in-office medication support.  I became involved with Northwind (formerly PCA in 2003) and have since worked to find ways to better serve our clinic customers and their patients.  Today, Northwind supports hundreds of student health centers, community health centers and physician practices around the country.  My goal with this blog is to offer perspective on physician dispensing and discuss ways practitioners can enhance and grow their clinics.

Schedule a free claims analysis now.

Let’s Talk now

Leader in AI-driven health benefits navigation Healthee partners with Northwind

Katherine Lurk | Mar 28th, 2025
A game-changer for employers looking to cut costs and gain control With healthcare costs continuing to rise, employers are seeking new ways to rein in spending without sacrificing the quality of benefits. This partnership enables Healthee clients to optimize prescription drug management, reducing costs through preferable generic drug pricing, high-touch chronic care programs, and more. … more »

continue reading

Healthcare Storm 2025: What Will It Be?

Phillip Berry | Jan 1st, 2025
When it comes to American healthcare, we’ve become really good at highlighting its failings. Watching the flurry of lamentations, frustrations, denigrations, and prognostications, over the last few weeks, would lead any rational person to believe that nothing is working in our healthcare system. And, not only is it “not working,” many people conclude that it … more »

continue reading

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading